Latest News and Press Releases

New Haven, Conn, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics announced today that it has entered into a $30 million growth capital debt financing agreement with Hercules Technology Growth...

NEW HAVEN, Conn. and Sao Paolo, Brazil, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics and Eurofarma Laboratórios, one of the largest pharmaceutical companies in Brazil, announced that...

New Haven, Conn, Jan. 7, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced positive top-line results from the first of two Phase 3 PROCEED studies (study RX-3341-302, NCT01811732) to...

NEW HAVEN, Conn, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced results from in vitro studies that highlight the potential of delafloxacin, an investigational fluoroquinolone,...

NEW HAVEN, Conn, Sept. 6, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced results of a Phase 1 study of delafloxacin, an investigational fluoroquinolone, in healthy adults that...

NEW HAVEN, Conn, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced that an additional three abstracts have been accepted as late-breakers at the annual Interscience Conference...

NEW HAVEN, Conn, Aug. 14, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced the appointment of Christopher Kiritsy to the Company's Board of Directors. Mr. Kiritsy is currently president,...

NEW HAVEN, Conn, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced top-line results of a Phase 1 clinical study that demonstrated that the administration of single doses of...

NEW HAVEN, Conn, July 24, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced that the company and investigators will be making eight presentations at the annual Interscience Conference...

NEW HAVEN, Conn, June 17, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced that CEO Mary Szela will be presenting at the annual JMP Securities Healthcare Conference in New York, NY....